PrimeGen Biotech LLC and Unidym Inc., a majority owned subsidiary of Arrowhead Research Corporation have signed an agreement to focused on exploring new applications for carbon nanotubes in stem cell medicine.
Unidym is a leader in the manufacture and application of carbon nanotubes (CNTs), a novel material with extraordinary electrical, thermal, and mechanical properties.
Unidym brings to this partnership its leadership in carbon nanotube science, technology and production.
PrimeGen have for the first time, successfully used non viral technologies to reprogram adult human cells into stem cells that the company refers to as intermediate iPS cells. Unlike embryonic stem cells, induced pluripotent stem cells, or iPS cells, are derived directly from a patient's adult human tissues such as skin. PrimeGen will have access to Unidym's extensive patent portfolio, services and industry standard HIPCO carbon nanotubes.
PrimeGen Biotech is dedicated to the research and therapeutic applications of adult stem cells, leading to individualized patient therapies. Entering its fifth year of operations at the pre clinical stage of product development, the company specializes in two core technologies: germ line stem cells and therapeutic reprogramming. Pioneering work on induced pluripotent stem cells (iPS cells), positions PrimeGen as a leader in moving this breakthrough from research to therapy.